PDF(Pubmed)
Abstract：
The concept of early osteoarthritis (OA) is based on the expectation that if found and treated in the early stage, the progression of the disease might be arrested before affected joints are irreversibly destroyed. This notion of early OA detection can also bear meaning for regenerative medicine (RM) which is purposed to cure a disease by regenerating the damaged tissue. RM can be a category of disease-modifying osteoarthritis drugs (DMOADs) and provide an attractive treatment for OA, restoring structural damage incurred during the disease by repopulating cells and reconstituting. While cell therapy including the use of stem cells is conflated with RM, it may also comprise gene therapy, exosomes, and other cell or cell-free-derived products. Considering that not all early OA will become advanced OA and that RM has a characteristic of personalized medicine, it would be very important to foretell, even roughly, which patients will progress rapidly and who will favorably respond to regenerative treatment. Subclassification and comprehensive endotyping or phenotyping (E/P) can be very helpful in detecting the population who would benefit from RM as well as rapid progressors who need closer monitoring.
摘要：
早期骨关节炎（OA）的概念是基于这样的期望，即如果在早期发现并治疗，在受影响的关节被不可逆转地破坏之前，疾病的进展可能会被阻止。这种早期OA检测的概念对于再生医学（RM）也具有意义，该医学旨在通过再生受损组织来治愈疾病。RM可以是一类疾病缓解性骨关节炎药物（DMOAD），并为OA提供有吸引力的治疗方法，通过重新填充细胞和重建来恢复疾病期间发生的结构损伤。虽然包括使用干细胞在内的细胞疗法与RM混为一谈，它也可能包括基因治疗，外泌体,和其他细胞或无细胞衍生产品。考虑到并非所有早期OA都将成为高级OA，并且RM具有个性化医疗的特征，预言非常重要，甚至粗略地，哪些患者会快速进展，哪些患者会对再生治疗反应良好。亚分类和全面的内分型或表型（E/P）可以非常有助于检测将受益于RM的人群以及需要密切监测的快速进展者。
